Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2018-10-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
关于取得医疗器械注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate from a regulatory authority. It details the product name, registration number, validity period, product use, comparison with similar products, impact on company performance, and risk warnings. The document is short (1114 characters) and serves as an official notification rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory certifications. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category, which is the Regulatory Filings (RNS) category as a fallback for miscellaneous filings that do not fit other specific categories.
2018-10-11 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle funds. It details the company's purchase and management of various financial products such as open-ended wealth management products, structured deposits, and fixed income products, including amounts, dates, and yields. The document is relatively short (1835 characters) and focuses on financial updates related to cash management activities rather than presenting comprehensive financial statements or audit results. It does not contain full financial reports, audit opinions, or regulatory certifications. The content fits best under Capital/Financing Update (CAP) as it provides updates on the company's financing activities and capital management through investment in financial products.
2018-10-08 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the company's use of idle raised funds for cash management, detailing purchases and redemptions of financial products such as structured deposits and wealth management products. It includes specific dates, amounts, and yields but does not contain comprehensive financial statements or detailed financial performance analysis. The document is relatively short (1888 characters) and serves as an update on financing activities related to idle funds rather than a full financial report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-10-08 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle funds. It details the company's purchase and redemption of various financial products such as structured deposits and open-ended wealth management products, including amounts, dates, and returns. The document is relatively short (2459 characters) and focuses on updates about financing activities related to cash management and investment products. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content aligns with updates on company financing activities and capital management. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-09-03 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the company's use of idle raised funds for cash management, detailing purchases and redemptions of financial products such as bank wealth management products and structured deposits. It includes specific dates, amounts, and yields but does not contain comprehensive financial statements or detailed financial performance analysis. The document is relatively short (1691 characters) and serves as an update on financing activities related to the use of raised funds. This fits the description of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP.
2018-09-03 Chinese
关于控股孙公司取得医疗器械经营许可证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its controlling subsidiary obtaining a medical device business license from a regulatory authority. It details the license number, scope, and validity period, and discusses the impact on the company. There is no financial data, no mention of annual or quarterly reports, no voting results, no management changes, no legal proceedings, no capital changes, and no earnings information. The document is a regulatory announcement about a business license approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories. The document length is short (1120 characters), and it is not an announcement of a report publication but a standalone announcement of a license approval.
2018-08-29 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.